BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA.
Boyle EM, et al. Among authors: tytarenko rg.
Clin Cancer Res. 2020 May 15;26(10):2422-2432. doi: 10.1158/1078-0432.CCR-19-1507. Epub 2020 Jan 27.
Clin Cancer Res. 2020.
PMID: 31988198
Free article.